First-Line Immunotherapy for Metastatic Solid Tumors
The optimal first-line immunotherapy regimen depends critically on tumor type and molecular characteristics, but for most metastatic solid tumors without specific oncogenic drivers, combination checkpoint blockade (nivolumab plus ipilimumab) or PD-1/PD-L1 inhibitor plus chemotherapy generally provides superior outcomes compared to monotherapy, though at the cost of increased toxicity.
Tumor-Specific Recommendations
Metastatic Melanoma
For BRAF wild-type melanoma, start with nivolumab plus ipilimumab combination therapy 1. The ESMO consensus strongly supports this approach, with 100% expert agreement. While this combination carries higher toxicity than monotherapy, it offers the best chance for durable disease control.
For BRAF-mutated melanoma, the decision is more nuanced:
Prioritize immunotherapy (anti-PD-1 monotherapy or nivolumab/ipilimumab) if the patient can tolerate treatment for several months and you're seeking long-term durable control 1. Immunotherapy provides very long-term disease control even after stopping treatment—the most compelling reason to use it first-line.
Use BRAF/MEK inhibitors first only when rapid disease control is essential: high tumor burden, elevated LDH, symptomatic disease, poor performance status, or rapidly progressive disease 1. These patients need the 70% response rate and rapid symptom relief that targeted therapy provides.
Critical caveat: The NCCN 2021 guidelines now recommend nivolumab 3 mg/kg plus ipilimumab 1 mg/kg (NIVO3/IPI1) over the FDA-approved nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1/IPI3) dosing 2. This modified regimen significantly reduces grade 3-5 toxicity while maintaining efficacy, though longer follow-up is needed to confirm therapeutic equivalence.
Metastatic Non-Small Cell Lung Cancer (Non-Oncogene Addicted)
For patients with ECOG PS 0-1 and no contraindications to immunotherapy, use platinum-based chemotherapy plus PD-1/PD-L1 blockade regardless of PD-L1 status 3. Approved combinations include:
- Pembrolizumab plus platinum-based chemotherapy (squamous and non-squamous)
- Atezolizumab ± bevacizumab plus chemotherapy (non-squamous only)
- Nivolumab plus ipilimumab plus chemotherapy (squamous)
- Cemiplimab plus chemotherapy (both histologies)
Exception for PD-L1 ≥50%: Anti-PD-1 monotherapy (pembrolizumab or nivolumab) is an acceptable alternative 3, though recent real-world meta-analysis suggests chemo-immunotherapy may provide superior outcomes even in this subset, particularly for never-smokers, women, and ECOG PS 0 patients 4.
For BRAF V600E-mutated NSCLC specifically: Recent 2025 data demonstrates that first-line immunotherapy with or without chemotherapy provides superior overall survival (40.9 vs 25.2 months) compared to BRAF/MEK inhibitors 5. This benefit is most pronounced in patients with smoking history, PD-L1 ≥1%, age ≥70 years, TP53 co-mutations, and absence of brain metastases.
Metastatic Urothelial Carcinoma
Enfortumab vedotin plus pembrolizumab is now the preferred first-line regimen for advanced/metastatic urothelial carcinoma, regardless of platinum eligibility 6. This represents a major 2024 update with Level I, Grade A evidence and ESMO-MCBS score of 4.
Alternative for patients unable to receive enfortumab vedotin:
- Nivolumab plus gemcitabine-cisplatin (cisplatin-eligible only) 6
- Platinum-based chemotherapy followed by avelumab maintenance (for non-progressors) 6
Single-agent checkpoint inhibitors should NOT be routinely recommended in first-line advanced disease 6.
MSI-H/dMMR Metastatic Colorectal Cancer
Pembrolizumab monotherapy is the most mature first-line standard with superior progression-free and overall survival versus chemotherapy and well-characterized long-term safety 7.
Nivolumab plus ipilimumab provides the strongest evidence for dual checkpoint blockade and demonstrates superiority over both chemotherapy and nivolumab monotherapy in randomized trials 7. However, this comes with substantially higher immune-related toxicity and treatment discontinuation rates.
Selection factors:
- Use pembrolizumab for: lower disease burden, good performance status, desire to minimize toxicity
- Consider nivolumab/ipilimumab for: high disease burden, aggressive disease kinetics, ability to manage immune toxicity
Key Clinical Decision Points
Performance Status Considerations
- ECOG PS 0-1: Full combination regimens appropriate
- ECOG PS 2: Consider modified approaches; combination chemo-immunotherapy may not provide benefit 3
- ECOG PS ≥3: Best supportive care or clinical trial
Biomarker-Driven Decisions
PD-L1 expression (for NSCLC):
- ≥50%: Monotherapy acceptable but chemo-immunotherapy may be superior in specific subgroups 4
- 1-49%: Combination chemo-immunotherapy preferred
- <1%: Combination chemo-immunotherapy required
Tumor mutational burden (for melanoma):
- TMB-high (≥10 mut/Mb): Predicts superior outcomes on checkpoint inhibitors 8
- TMB 10-19 mut/Mb with BRAF mutation: Dual checkpoint blockade shows greatest benefit
- TMB ≥20 mut/Mb with BRAF mutation: Anti-PD-1 monotherapy may be preferable 8
Common Pitfalls to Avoid
Do not switch from effective targeted therapy to immunotherapy outside clinical trials 1. This carries risk of discontinuing effective treatment for potentially lower efficacy.
Do not use single-agent ipilimumab as first-line therapy for melanoma—it has been superseded by anti-PD-1 monotherapy or combination regimens 9.
Do not rechallenge with anti-PD-1 after progression on enfortumab vedotin-pembrolizumab without further evidence 6.
Do not omit molecular testing before starting immunotherapy—actionable mutations (EGFR, ALK, ROS1, BRAF, FGFR) may warrant targeted therapy instead.
Toxicity Management Considerations
The modified NIVO3/IPI1 dosing for melanoma significantly reduces grade 3-5 treatment-related adverse events compared to NIVO1/IPI3 (34% vs 55%, P=0.006) 2. When using dual checkpoint blockade, ensure:
- Baseline organ function assessment
- Patient education on immune-related adverse events
- Rapid access to corticosteroids
- Multidisciplinary toxicity management protocols